Barrier and driver analysis
Explore how referral pathways, stakeholder perspectives and evidence needs differ by market, and identify the questions your medical, access and commercial teams need to address.
Builds on the rare disease landscaping baseline.
Local barriers, market by market.
Barrier and driver analysis looks at how diagnosis and referral, specialist and centre dynamics, and evidence expectations differ across Germany, France, Italy, Spain, the UK, the Netherlands and the Nordics, so your medical, access and commercial teams know which questions each market raises. Specialist pricing, reimbursement submissions and HTA dossier development are scoped separately with the appropriate expertise.
Tangible deliverables you can act on
Barrier and driver register
Prioritised per market, with the source and confidence behind each entry.
Stakeholder perspective summary
What clinicians, payers and patient representatives told us, attributed as views rather than fact.
Country comparison
How pathways, evidence expectations and local conditions differ across the markets in scope.
Findings and implications
Prioritised findings, open questions and what they imply for your next steps.
What barrier and driver analysis covers
Diagnosis and referral barriers
Where patients are missed, delayed or referred elsewhere, and what stands in the way of earlier identification.
Specialist and treatment-centre dynamics
Which centres and specialists carry the pathway, how they work together, and what governs their treatment choices.
Stakeholder perspectives on evidence and adoption
What clinicians, payers and patient representatives say they need to see, and where their expectations differ from each other.
Country-specific differences
How pathways, evidence expectations and local conditions vary across the markets in scope.
Prioritised findings and implications
The findings we judge most consequential, the uncertainty attached to each, and the questions your teams should address next.
How the engagement runs
Scope
We align on the priority markets, decision points and the adoption questions the analysis needs to answer.
Investigate
We engage stakeholders across the pathway to surface barriers and drivers, and record where views converge and where they conflict.
Prioritise
We set out findings, uncertainties and implications, prioritised for your medical, access and commercial teams.
Scope
We align on the priority markets, decision points and the adoption questions the analysis needs to answer.
Investigate
We engage stakeholders across the pathway to surface barriers and drivers, and record where views converge and where they conflict.
Prioritise
We set out findings, uncertainties and implications, prioritised for your medical, access and commercial teams.
What you walk away with.
Engagement timeline
Deliverable: a prioritised barrier and driver register per market, with findings, uncertainties and implications
- A market-by-market view of the diagnosis and referral barriers we identified, and the evidence behind each.
- A read on specialist and treatment-centre dynamics in the markets in scope.
- Documented stakeholder perspectives on evidence and adoption, including where they conflict.
- Prioritised findings, stated uncertainty and the questions your teams should address next.
Barrier and driver analysis, answered
What is a barrier and driver analysis?
It is structured research into the clinical, system and stakeholder conditions affecting adoption of a product in a given market. Each finding is evidenced, prioritised and reported with the confidence behind it.
How is it different from a launch readiness checklist?
A checklist confirms whether internal launch tasks are done. A barrier and driver analysis looks outward at the system: what the field will actually accept or reject, and where the moves with the most impact sit.
When should we commission it?
Twelve to twenty-four months before launch is typical, while there is still time to shape evidence, access and field plans. It is also useful post-launch when uptake is below expectation.
How does stakeholder perception feature in the analysis?
Stakeholder views are reported alongside clinical and system findings. We record how clinicians, payers and patients frame your product, the alternatives and the cost of change, attributed as views rather than fact, and note where they conflict.
What do we receive at the end?
A prioritised barrier and driver register per market, a documented summary of stakeholder views, a country comparison, and the findings, open questions and implications for your medical, access and commercial teams.
Which markets do you cover?
We focus on priority European markets and tailor the country mix to your launch plan. We can extend to other regions on request.
Insights behind this work
- Why we focus on product-system fitProduct-market fit is necessary in healthcare, but it is not enough. Strong products can still fail to reach patients if the surrounding system is not ready to adopt and act on them. That missing piece is product-system fit.
- How we measure ecosystem readinessReadiness sounds soft. We make it a number you can manage.
Discuss your market's research needs
Tell us the disease area, the priority markets and the decision in front of you, and we will set out what a scoped engagement would cover.